Vietnam Medical and Pharmaceutical Investment JSC (HOSE:JVC)

HOSE:JVC Financials Overview

Financials in millions VND. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2017	FY 2016
Period Ending	Mar 31, 2026	Dec 31, 2025	Jan 1, 2025	Jan 1, 2024	Mar 31, 2017	Mar 31, 2016
Revenue Revenue Growth	741,124	763,153	611,540	576,287	499,432	507,338
Revenue Growth	9.92%	24.79%	6.12%	15.39%	-1.56%	-43.20%
Gross Profit Gross Profit Growth	142,114	148,917	147,572	138,863	93,981	3,386
Operating Income Operating Income Growth	49,299	52,796	36,510	27,308	-26,745	-1,192,003
Net Income Net Income Growth	36,861	49,945	40,282	52,634	-31,694	-1,335,782
Earnings Per Share EPS Growth	327.65	443.96	358.00	467.86	-281.73	-11873.60
EPS Growth	-36.29%	24.01%	-23.48%	-	-	-

Revenue by Segment

Chart

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Jan 1, 2025
Providing Services Providing Services Growth	59,619	50,691
Medical Device Integration Activities Medical Device Integration Activities Growth	29,097	67,729
Sale of Medical Machinery and Equipment Sale of Medical Machinery and Equipment Growth	674,437	493,120
Total Total Growth	763,153	611,540

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2017	FY 2016
Period Ending	Mar 31, 2026	Dec 31, 2025	Jan 1, 2025	Jan 1, 2024	Mar 31, 2017	Mar 31, 2016
Cash & Investments Cash & Investments Growth	44,035	29,228	19,582	153,516	37,500	16,557
Total Debt Total Debt Growth	390,297	303,082	140,829	92,726	35,721	51,611
Net Cash (Debt) Net Cash Growth	-346,263	-273,854	-121,247	60,790	1,778	-35,054
Net Cash Growth	-	-	-	3318.23%	-	-
Net Cash Per Share Net Cash Per Share Growth	-3077.88	-2434.25	-1077.75	540.36	15.81	-311.59

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2017	FY 2016
Period Ending	Mar 31, 2026	Dec 31, 2025	Jan 1, 2025	Jan 1, 2024	Mar 31, 2017	Mar 31, 2016
Operating Cash Flow Operating Cash Flow Growth	124,705	-88,546	85,753	-6,474	76,126	-319,023
Capital Expenditures CapEx Growth	-38,353	-41,862	-16,594	-43,363	-42,587	-8,810
Free Cash Flow Free Cash Flow Growth	86,352	-130,408	69,159	-49,837	33,540	-327,834
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2017	FY 2016
Period Ending	Mar 31, 2026	Dec 31, 2025	Jan 1, 2025	Jan 1, 2024	Mar 31, 2017	Mar 31, 2016
Gross Margin	19.18%	19.51%	24.13%	24.10%	18.82%	0.67%
Operating Margin	6.65%	6.92%	5.97%	4.74%	-5.36%	-234.95%
Pretax Margin	6.11%	8.05%	9.63%	9.70%	-5.94%	-263.34%
Profit Margin	4.97%	6.54%	6.59%	9.13%	-6.35%	-263.29%
FCF Margin	11.65%	-17.09%	11.31%	-8.65%	6.72%	-64.62%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2017	FY 2016
Period Ending	Jul 25, 2026	Dec 31, 2025	Jan 1, 2025	Jan 1, 2024	Mar 31, 2017	Mar 31, 2016
PE Ratio	9.16	13.72	10.61	7.22	-	-
Forward PE	-	9.64	9.64	9.64	9.64	9.64
P/FCF Ratio	3.91	-	6.18	-	11.64	-
PS Ratio	0.46	0.90	0.70	0.66	0.78	1.02

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 24, 2026

Data Sources Report a data error